11MO Final data from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3) and pembrolizumab in 2nd-line metastatic NSCLC pts resistant to PD-1/PD-L1 inhibitors

Margarita Majem; M.D. Forster; Matthew Krebs; J. Peguero; Timothy Clay; E. Felip; Wade Iams; Patricia Roxburgh; B. Spéville; P. Bajaj; C. Mueller; F. Triebel

doi:10.1016/S1556-0864(23)00265-4

11MO Final data from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3) and pembrolizumab in 2nd-line metastatic NSCLC pts resistant to PD-1/PD-L1 inhibitors

Margarita Majem, M.D. Forster, Matthew Krebs, J. Peguero, Timothy Clay, E. Felip, Wade Iams, Patricia Roxburgh, B. Spéville, P. Bajaj, C. Mueller, F. Triebel

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Pages (from-to)	S43-S44
Journal	Journal of Thoracic Oncology
Volume	18
DOIs	https://doi.org/10.1016/S1556-0864(23)00265-4
Publication status	E-pub ahead of print - 1 Apr 2023

Access to Document

10.1016/S1556-0864(23)00265-4

Cite this

Majem, M., Forster, M. D., Krebs, M., Peguero, J., Clay, T., Felip, E., Iams, W., Roxburgh, P., Spéville, B., Bajaj, P., Mueller, C., & Triebel, F. (2023). 11MO Final data from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3) and pembrolizumab in 2nd-line metastatic NSCLC pts resistant to PD-1/PD-L1 inhibitors. Journal of Thoracic Oncology, 18, S43-S44. Advance online publication. https://doi.org/10.1016/S1556-0864(23)00265-4

@article{48bb459d804b4b7f9d0cdd5029f33ed9,

title = "11MO Final data from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3) and pembrolizumab in 2nd-line metastatic NSCLC pts resistant to PD-1/PD-L1 inhibitors",

author = "Margarita Majem and M.D. Forster and Matthew Krebs and J. Peguero and Timothy Clay and E. Felip and Wade Iams and Patricia Roxburgh and B. Sp{\'e}ville and P. Bajaj and C. Mueller and F. Triebel",

year = "2023",

month = apr,

day = "1",

doi = "10.1016/S1556-0864(23)00265-4",

language = "English",

volume = "18",

pages = "S43--S44",

journal = "Journal of Thoracic Oncology",

issn = "1556-0864",

publisher = "Elsevier BV",

}

Majem, M, Forster, MD, Krebs, M, Peguero, J, Clay, T, Felip, E, Iams, W, Roxburgh, P, Spéville, B, Bajaj, P, Mueller, C & Triebel, F 2023, '11MO Final data from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3) and pembrolizumab in 2nd-line metastatic NSCLC pts resistant to PD-1/PD-L1 inhibitors', Journal of Thoracic Oncology, vol. 18, pp. S43-S44. https://doi.org/10.1016/S1556-0864(23)00265-4

11MO Final data from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3) and pembrolizumab in 2nd-line metastatic NSCLC pts resistant to PD-1/PD-L1 inhibitors. / Majem, Margarita; Forster, M.D.; Krebs, Matthew et al.
In: Journal of Thoracic Oncology, Vol. 18, 01.04.2023, p. S43-S44.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - 11MO Final data from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3) and pembrolizumab in 2nd-line metastatic NSCLC pts resistant to PD-1/PD-L1 inhibitors

AU - Majem, Margarita

AU - Forster, M.D.

AU - Krebs, Matthew

AU - Peguero, J.

AU - Clay, Timothy

AU - Felip, E.

AU - Iams, Wade

AU - Roxburgh, Patricia

AU - Spéville, B.

AU - Bajaj, P.

AU - Mueller, C.

AU - Triebel, F.

PY - 2023/4/1

Y1 - 2023/4/1

U2 - 10.1016/S1556-0864(23)00265-4

DO - 10.1016/S1556-0864(23)00265-4

M3 - Meeting Abstract

SN - 1556-0864

VL - 18

SP - S43-S44

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

ER -